MELA Sciences, a Leader in Melanoma Diagnostics, Appoints Rose Crane as President and Chief Executive Officer and a Director,

MELA Sciences, a Leader in Melanoma Diagnostics, Appoints Rose Crane as
President and Chief Executive Officer and a Director, Effective as of Monday,
November 11th

IRVINGTON, N.Y., Nov. 6, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercializing MelaFind®, an optical diagnostic device using proprietary
technology that enables dermatologists to "see" below the surface of a
patient's skin to aid in the diagnosis of melanoma, today announced that the
Company has appointed Rose Crane as its President and Chief Executive Officer
and a director, effective as of November 11, 2013. At such time Interim CEO,
Robert Coradini, will assume the Chairman's role and thereafter is planned to
provide ongoing active consulting while current Chairman, David Stone, will
resume his director's role on the Board.

Rose Crane was most recently Partner at Appletree Partners where she was
responsible for assessing and recommending products to build the Appletree
portfolio, consisting of pharmaceutical products, medical devices and
healthcare services. Previously, Rose was Chief Executive Officer and
President of Epocrates, where she developed the strategic plan to advance and
promote growth at the company.She also organized and directed the efforts for
a successful IPO for Epocrates in 2011. Rose served as Company Group Chairman
of OTC/Nutritionals at Johnson & Johnson leading the largest worldwide OTC
company. She also spent 20 years of her career at Bristol-Myers Squibb, most
recently as President of US Primary Care where she managed an operating unit
with annual sales of $7.5 billion.

"Rose is an experienced healthcare industry executive with an excellent track
record for growing organizations, driving corporate development activities and
successfully building commercial platforms to create value for shareholders,"
said Robert Coradini, Interim CEO of MELA Sciences. "We believe that her
leadership and operational expertise will lead MELA Sciences during the next
stage of our evolution in building our business and in the pursuit of
establishing MelaFind as a standard of care in the fight against melanoma."

"I am pleased to be joining MELA Sciences, a company that is at an inflection
point in its growth trajectory, building both a talented workforce and strong
relationships with clinical partners and customers," said Rose Crane. "I look
forward to working with the Board and the management team to strengthen the
Company's operational performance, drive the commercialization of MelaFind and
position MELA Sciences to achieve its full potential."

MelaFind is the first and only FDA-approved automated optical imaging device
for melanoma detection used by dermatologists and was recognized by the
Cleveland Clinic as a Top 10 Medical Innovation for 2013. MelaFind was
featured in the Wall Street Journal, and recently received national attention
on "The Rachael Ray Show". Consumers can learn more about the device or locate
a MelaFind dermatologist in their area by visiting www.melafind.com.

About MELA Sciences, Inc.

MelaFind is the first and only FDA approved automatic (algorithm-based)
optical diagnostic device for melanoma detection used by dermatologists.

MELA Sciences is an optical imaging medical device company focused on
dermatology diagnostics.Our first and flagship product is MelaFind, though we
plan to explore new uses and embodiments of the Company's innovative
technology. MelaFind is a non-invasive diagnostic tool to provide additional
information to dermatologists during melanoma skin examinations. The device
uses multispectral light from visible to near-infrared wavelengths to evaluate
skin lesions up to 2.5 mm beneath the skin. The device provides information on
a lesion's level of morphologic disorganization to provide additional
objective information that may be used by dermatologists in the biopsy
decision-making process. MelaFind has been approved by the US Food and Drug
Administration for use in the US. In addition, MelaFind has received CE Mark
approval and is approved for use in the European Union.

For more information on MELA Sciences, Inc., visit www.melasciences.com.

Safe Harbor:

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at www.sec.gov and
www.melasciences.com.

CONTACT: For further information contact:
        
         Investors
         Lynn Pieper
         Westwicke Partners
         415-202-5678
        
         Media
         Erica Sperling
         Rpr Marketing Communications
         212-317-1462
         Erica.Sperling@rprmc.com